WO2000012623A3 - Utilisation - Google Patents

Utilisation Download PDF

Info

Publication number
WO2000012623A3
WO2000012623A3 PCT/EP1999/006219 EP9906219W WO0012623A3 WO 2000012623 A3 WO2000012623 A3 WO 2000012623A3 EP 9906219 W EP9906219 W EP 9906219W WO 0012623 A3 WO0012623 A3 WO 0012623A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
receptor antagonists
parkinson
disease
medicaments
Prior art date
Application number
PCT/EP1999/006219
Other languages
English (en)
Other versions
WO2000012623A2 (fr
Inventor
Carol Routledge
Original Assignee
Smithkline Beecham Plc
Carol Routledge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Carol Routledge filed Critical Smithkline Beecham Plc
Priority to AU59706/99A priority Critical patent/AU5970699A/en
Publication of WO2000012623A2 publication Critical patent/WO2000012623A2/fr
Publication of WO2000012623A3 publication Critical patent/WO2000012623A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

L'invention concerne l'utilisation d'antagonistes du récepteur de 5-HT6 dans la préparation de médicaments destinés au traitement de la maladie de Parkinson.
PCT/EP1999/006219 1998-08-28 1999-08-25 Utilisation WO2000012623A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59706/99A AU5970699A (en) 1998-08-28 1999-08-25 Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818914.5A GB9818914D0 (en) 1998-08-28 1998-08-28 Use
GB9818914.5 1998-08-28

Publications (2)

Publication Number Publication Date
WO2000012623A2 WO2000012623A2 (fr) 2000-03-09
WO2000012623A3 true WO2000012623A3 (fr) 2000-08-24

Family

ID=10838073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006219 WO2000012623A2 (fr) 1998-08-28 1999-08-25 Utilisation

Country Status (3)

Country Link
AU (1) AU5970699A (fr)
GB (1) GB9818914D0 (fr)
WO (1) WO2000012623A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790727B2 (en) 2007-11-02 2010-09-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
US6586592B2 (en) 2000-06-20 2003-07-01 Pharmacia & Upjohn Company Bis-arylsulfones
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
DE60142914D1 (de) * 2000-09-18 2010-10-07 Toa Eiyo Ltd N-substituierte benzothiophensulfonamid-derivate
EP1353914A2 (fr) 2001-01-16 2003-10-22 AstraZeneca AB Composes de chromone therapeutiques
NZ526697A (en) 2001-01-16 2005-05-27 Astrazeneca Ab Therapeutic heterocyclic compounds
CA2443724C (fr) * 2001-05-11 2009-11-03 Patrizia Caldirola Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
AU2002340804B2 (en) 2001-08-10 2008-04-03 F. Hoffmann-La Roche Ag Arylsulfonyl derivatives with 5-HT6 receptor affinity
DE60333351D1 (de) * 2002-03-15 2010-08-26 Toa Eiyo Ltd N-substituiertes benzothiophensulfonamidderivat
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
SG175187A1 (en) 2009-04-30 2011-11-28 Abbott Gmbh & Co Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CA2759491A1 (fr) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Composes de benzenesulfonanilide pour le traitement de troubles repondant a la modulation du recepteur 5-ht6 de la serotonine
WO2012059432A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6
WO2012059431A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine
MX2016005348A (es) * 2013-10-25 2016-08-11 Glaxosmithkline Llc Compuestos novedosos.
JP6992004B2 (ja) 2016-04-26 2022-02-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533267A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0815861A1 (fr) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides et leur utilisation
WO1998027081A1 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
WO1999002502A2 (fr) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Nouveaux composes
WO1999037623A2 (fr) * 1998-01-22 1999-07-29 Smithkline Beecham Plc Nouveaux composes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533267A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0815861A1 (fr) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides et leur utilisation
WO1998027081A1 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
WO1999002502A2 (fr) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Nouveaux composes
WO1999037623A2 (fr) * 1998-01-22 1999-07-29 Smithkline Beecham Plc Nouveaux composes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOURSON, ANNE ET AL: "Involvement of 5-HT6 receptors in nigro-striatal function in rodents", BR. J. PHARMACOL. (1998), 125(7), 1562-1566, 1998, XP000900090 *
BROMIDGE ET AL: "5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothioph enesulfonamide(SB-271046): A Potent, Selective, and Orally Bioavailable5-HT6 Receptor Antagonist", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 42, no. 2, 28 January 1999 (1999-01-28), pages 202 - 205-205, XP002109186, ISSN: 0022-2623 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; GUPTA Y.K. ET AL: "Therapeutic potentials of 5-HT receptor modulators.", XP002133179, retrieved from STN Database accession no. 94205555 *
INDIAN JOURNAL OF PHARMACOLOGY, (1994) 26/2 (94-107). *
SLEIGHT ET AL: "The 5-hydroxytryptamine-6 receptor: localisation and function", EXPERT OPINION ON THERAPEUTIC PATENTS,GB,ASHLEY PUBLICATIONS, vol. 8, no. 10, 1 October 1998 (1998-10-01), pages 1217 - 1224, XP002093843, ISSN: 1354-3776 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790727B2 (en) 2007-11-02 2010-09-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Also Published As

Publication number Publication date
WO2000012623A2 (fr) 2000-03-09
GB9818914D0 (en) 1998-10-21
AU5970699A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
WO2000012623A3 (fr) Utilisation
WO1999017755A3 (fr) Medicaments
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
HUP0004412A3 (en) Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
WO1995031985A3 (fr) Compositions pharmaceutiques contenant un antagoniste des opiaces et des sels de calcium, et leur utilisation dans le traitement de pathologies a mediation endorphinique
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0002902A3 (en) 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions
IL164839A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU4345297A (en) Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
ZA983602B (en) Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
HUP0002303A3 (en) Benzofurazan derivatives and their use for the preparation of pharmaceutical compositions which enhance ampa receptor activity
IL119417A0 (en) Drug for Parkinson's disease
AU2639299A (en) Remedies/preventives for parkinson's disease
NO20013645L (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjon av de perifere benzodiazepinreseptorer
EP1126850A4 (fr) Traitement des affections de la retine
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
CA2260863A1 (fr) Traitement de troubles d'ordre psychotique
ZA989615B (en) The use of TNF antagonists as drugs for treating septic 39disorders.
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
AU1146401A (en) Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye
ZA98484B (en) Use of beta3-adrenergic receptor agonists for the preparation of healing drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase